Dossier
vopimetostat
Coverage of vopimetostat in the Nexus archive.
- Tango Therapeutics stock surges on pancreatic cancer drug combo data
Tango Therapeutics' stock surged after a combination of vopimetostat and Revolution Medicines' daraxonrasib showed a 92% response rate in patients with advanced pancreatic cancer.
- STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate
A combination of Tango Therapeutics' vopimetostat and Revolution Medicines' daraxonrasib showed durable responses in most pancreatic cancer patients in an early-stage trial. Revolution's drug has demonstrated unprecedented outcomes, highlighting potential in oncology treatments.